{
    "2018-01-18": [
        [
            {
                "time": "2018-01-02",
                "original_text": "Top Research Reports for Apple, JPMorgan & AbbVie",
                "features": {
                    "keywords": [
                        "research reports",
                        "Apple",
                        "JPMorgan",
                        "AbbVie"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "technology",
                        "finance",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-03",
                "original_text": "Can These 4 Large-Cap Drug Stocks Deliver an Encore in '18?",
                "features": {
                    "keywords": [
                        "large-cap drug stocks",
                        "encore",
                        "2018"
                    ],
                    "sentiment_score": 0.65,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-04",
                "original_text": "J&J (JNJ) Hits New 52-Week High: What's Driving the Stock?",
                "features": {
                    "keywords": [
                        "JNJ",
                        "52-week high",
                        "driving stock"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-05",
                "original_text": "A Look into Amgen’s Collaborations in 2H17",
                "features": {
                    "keywords": [
                        "Amgen",
                        "collaborations",
                        "2H17"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-06",
                "original_text": "See what the IHS Markit Score report has to say about AbbVie Inc.",
                "features": {
                    "keywords": [
                        "IHS Markit Score",
                        "report",
                        "AbbVie"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-07",
                "original_text": "How Amgen’s Enbrel and Nplate Are Positioned for 2018",
                "features": {
                    "keywords": [
                        "Amgen",
                        "Enbrel",
                        "Nplate",
                        "2018"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-08",
                "original_text": "[$$] Buybacks, Pension Contributions and Savings: Companies Tout Tax Benefits",
                "features": {
                    "keywords": [
                        "buybacks",
                        "pension contributions",
                        "tax benefits"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "general"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}